The DOI matches its Crossref record; 399 of the 399 references it cites were found in a registry or an index.
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Open accessAbstract
Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness. Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression. The array of available rodent models is large and ranges from acute pharmacological models, such as the reserpine‐ or haloperidol‐treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro‐striatal pathway, such as the classical 6‐hydroxydopamine (6‐OHDA) rat and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse models. All of these have provided test beds in which new molecules for treating the motor symptoms of PD can be assessed. In addition, the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6‐OHDA‐lesioned rats with L‐DOPA has allowed for examination of the mechanisms responsible for treatment‐related dyskinesia in PD, and the detection of molecules able to prevent or reverse their appearance. Other toxin‐based models of nigro‐striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but whilst providing clues to disease pathogenesis, these are not so commonly used for drug development. The MPTP‐treated primate model of PD, which closely mimics the clinical features of PD and in which all currently used anti‐parkinsonian medications have been shown to be effective, is undoubtedly the most clinically‐relevant of all available models. The MPTP‐treated primate develops clear dyskinesia when repeatedly exposed to L‐DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man. Whether non‐dopaminergic drugs show the same degree of predictability of response is a matter of debate. As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed. A further generation of models aimed at mimicking the genetic causes of PD has also sprung up. Whilst these newer models have provided further clues to the disease pathology, they have so far been less commonly used for drug development. There is little doubt that the availability of experimental animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug‐related side effects that emerge with disease progression and chronic medication. However, so far, we have made little progress in moving into other pharmacological areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathology and biochemical change. Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression. The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic? This article aims to clarify the current position and highlight the strengths and weaknesses of available models. LINKED ARTICLES This article is part of a themed issue on Translational Neuropharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue‐4
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–399 of 399
Vila, M., Levy, R., Herrero, M.-T., Ruberg, M., Faucheux, B., Obeso, J. A., Agid, Y., & Hirsch, E. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00765.1997 · Cited by 158
Pendleton, R. G., Parvez, F., Sayed, M., & Hillman, R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.91 · Cited by 158
Mitchell, I., Cross, A. J., Sambrook, M. A., & Crossman, A. R. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90424-0 · Cited by 157
Gasmi, M., Herzog, C. D., Brandon, E. P., Cunningham, J. J., Ramirez, G. A., Ketchum, E. T., & Bartus, R. T. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300010 · Cited by 157
Kebabian, J. W., Britton, D. R., DeNinno, M. P., Perner, R. J., Smith, L. A., Jenner, P. G., Schoenleber, R. W., & Williams, M. J. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90556-j · Cited by 157
Self-citationOestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156
Timecourse of striatal re‐innervation following lesions of dopaminergic SNpc neurons of the rat
Stanić, D., Finkelstein, D. I., Bourke, D. W., Drago, J., & Horne, M. K. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02800.x · Cited by 155
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice
Jiang, C., Wan, X., He, Y., Pan, T., Jankovic, J. J., & Le, W. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.035 · Cited by 154
Henry, B., Duty, S., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00064-5 · Cited by 153
Self-citationDecreased NURR1 gene expression in patients with Parkinson's disease
Le, W., Pan, T., Huang, M., Xu, P., Xie, W., Zhu, W., Zhang, X., Deng, H., & Jankovic, J. J. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.007 · Cited by 152
Ekstrand, M. I., & Galter, D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70811-9 · Cited by 151
Karunakaran, S., Saeed, U., Mishra, M., Valli, R. K., Joshi, S. D., Meka, D. P., Seth, P., & Ravindranath, V. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4511-08.2008 · Cited by 150
parkin counteracts symptoms in a Drosophila model of Parkinson's disease
Haywood, A. F. M., & Staveley, B. E. (2004) · BMC Neuroscience · doi:10.1186/1471-2202-5-14 · Cited by 150
Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Rascol, O., Arnulf, I., Paul, H. P., Brefel‐Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A. M., Descombes, S., Bejjani, B.-P. W., Fabre, N., et al. (2001) · Movement Disorders · doi:10.1002/mds.1143 · Cited by 149
The rationale for the use of dopamine agonists in Parkinson's disease
Jenner, P. G. (1995) · Neurology · doi:10.1212/wnl.45.3_suppl_3.s6 · Cited by 149
Self-citationPreclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist
Eden, R. J., Costall, B., Domeney, A. M., Gerrard, P. A., Harvey, C. A., Kelly, M. E., Naylor, R. J., Owen, D. A. A., & Wright, A. E. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90603-y · Cited by 146
Drug-induced Valvulopathy: An Update
Elangbam, C. S. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378027 · Cited by 146
Sundström, E., Fredriksson, A., & Archer, T. (1990) · Brain Research · doi:10.1016/0006-8993(90)91656-2 · Cited by 145
de Zafra, C. L. Z., Nordstroem, V. K., Briedrick, L. A., Hoernig, G. R., Granholm, A., & Bickford, P. C. (2000) · The Journal of Comparative Neurology · Cited by 143
Selective Agenesis of Mesencephalic Dopaminergic Neurons in Nurr1-Deficient Mice
Le, W., Conneely, O. M., Zou, L., He, Y., Cárdenas, O. S., Jankovic, J. J., Mosier, D. R., & Appel, S. H. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7191 · Cited by 141
Herrero, M. T., Augood, S. J., Hirsch, É. C., Javoy-Agid, F., Luquín, M. R., Agid, Y., Obeso, J. A., & Emson, P. C. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00120-8 · Cited by 141
Kordower, J. H., Kanaan, N. M., Chu, Y., Suresh Babu, R., Stansell, J., Terpstra, B. T., Sortwell, C. E., Steece-Collier, K., & Collier, T. J. (2006) · Annals of Neurology · doi:10.1002/ana.20935 · Cited by 141
Heeringa, M. J., & Abercrombie, E. D. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010192.x · Cited by 141
Preventing levodopa-induced dyskinesias.
Olanow, C. W., & Obeso, J. A. (2000) · PubMed · Cited by 140
Drosophila models pioneer a new approach to drug discovery for Parkinson's disease
Whitworth, A. J., Wes, P. D., & Pallanck, L. J. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03693-7 · Cited by 140
The evolution and origin of motor complications in Parkinson's disease.
Ja, O., Rodríguez‐Oroz, M., Chaná, P., Lera, G., Rodriguez, M., & Cw, O. (2000) · PubMed · Cited by 140
Mierau, J., & Schingnitz, G. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90024-x · Cited by 139
Wang, C., Lu, R., Ouyang, X., Ho, M. W. L., Chia, W. N., Yu, F., & Lim, K. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0218-07.2007 · Cited by 139
Mass fragmentography of dopamine and 6-hydroxydopamine
Curtius, H. ‐., Wolfensberger, M., Steinmann, B. U., Redweik, U., & Siegfried, J. (1974) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)90882-3 · Cited by 138
Dopamine agonists in Parkinson's disease: a look at apomorphine
Lees, A. J. (1993) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1993.tb00226.x · Cited by 138
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinsonʼs disease
Jenner, P. G. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312001-00002 · Cited by 137
Self-citationGibrat, C., Saint‐Pierre, M., Bousquet, M., Lévesque, D., Rouillard, C., & Cicchetti, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06072.x · Cited by 136
Iravani, M. M., Leung, C. C. M., Sadeghian, M., Haddon, C. O., Rose, S., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04220.x · Cited by 135
Self-citationPothakos, K., Kurz, M. J., & Lau, Y.-S. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-6 · Cited by 134
Costa, G., Abin-Carriquiry, J. A., & Dajas, F. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03087-0 · Cited by 134
Kirik, D., Georgievska, B., Rosenblad, C., & Björklund, A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01534.x · Cited by 133
McNaught, K. S. P., & Jenner, P. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732469.x · Cited by 132
Self-citationThe transcription factor PITX3 is associated with sporadic Parkinson's disease
Fuchs, J., Mueller, J. C., Lichtner, P., Schulte, C., Munz, M., Berg, D., Wüllner, U., Illig, T., Sharma, M., & Gasser, T. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.014 · Cited by 132
Meredith, G. E., Totterdell, S., Beales, M., & Meshul, C. K. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.06.005 · Cited by 132
Bianco, C. L., Déglon, N., Pralong, W. F., & Aebischer, P. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.06.008 · Cited by 132
MitoPark mice mirror the slow progression of key symptoms and L‐DOPA response in Parkinson's disease
Galter, D., Pernold, K., Yoshitake, T., Lindqvist, E., Hoffer, B. J., Kehr, J., Larsson, N., & Olson, L. (2009) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2009.00542.x · Cited by 129
Xi, Y., Ryan, J., Noble, S., Yu, M., Yilbas, A. E., & Ekker, M. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07091.x · Cited by 128
Degkwitz, R., Frowein, R. A., Kulenkampff, C., & Mohs, U. (1960) · Journal of Molecular Medicine · doi:10.1007/bf02189076 · Cited by 126
Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125
Varastet, M., RICHE, D., Mazière, M., & Hantraye, P. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90006-x · Cited by 124
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates
Bibbiani, F., Costantini, L. C., Patel, R., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.013 · Cited by 123
Clarke, C. E., Sambrook, M. A., Mitchell, I., & Crossman, A. R. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90041-4 · Cited by 122
Non-dopaminergic treatments in development for Parkinson's disease
Fox, S. H., Brotchie, J. M., & Lang, A. E. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70214-x · Cited by 122
Perumal, A. S., Gopal, V. B., Tordzro, W. K., Cooper, T. B., & Cadet, J. L. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90142-k · Cited by 120 · cited 2×
“…(ROS) such as H2O2 (Mazzio et al., 2004), to reduce striatal levels of antioxidant enzymes [total glutathione (GSH) or superoxide dismutase] (Perumal et al., 1992; Kunikowska and Jenner, 2001), to elevate levels of iron 1362 British Journal of Pharmacology (2011) 164 1357–1391 in the SN…”
BackgroundYoshimura, N., Mizuta, E., Kuno, S., Sasa, M., & Yoshida, O. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90151-r · Cited by 120
Jenner, P. G. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00115-3 · Cited by 119
Self-citationMAZZIO, E. A., Reams, R., & Soliman, K. F. A. (2004) · Brain Research · doi:10.1016/j.brainres.2003.12.034 · Cited by 118
Vila, M., Lévy, R., Herrero, M. T., Faucheux, B. A., Obeso, J. A., Agid, Y., & Hirsch, É. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00549-8 · Cited by 118
l-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats
Alam, M., & Schmidt, W. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.12.021 · Cited by 118
Lack of nigrostriatal pathology in a rat model of proteasome inhibition
Manning-Bog, A., Reaney, S. H., Chou, V., Johnston, L. C., McCormack, A. L., Johnston, J. A., Langston, J. W., & Monte, D. A. D. (2006) · Annals of Neurology · doi:10.1002/ana.20938 · Cited by 118
Functional anatomy of movement disorders
Crossman, A. R. (2000) · Journal of Anatomy · doi:10.1046/j.1469-7580.2000.19640519.x · Cited by 117
Hung, H.-C., & Lee, E. H. Y. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00062-9 · Cited by 116
Elsworth, J. D., Taylor, J. R., Sladek, J. R., Collier, T. J., Redmond, D. E., & Roth, R. H. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00437-6 · Cited by 115
Nisbet, A. P., Föster, O., Kingsbury, A. E., Eve, D. J., Daniel, S. E., MARSDEN, C. D., & Lees, A. J. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00606-6 · Cited by 115
Proteasomal activity in brain differs between species and brain regions and changes with age.
Zeng, B.-Y., Medhurst, A. D., Jackson, M., Rose, S., & Jenner, P. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.01.008 · Cited by 113
Self-citationLevodopa-induced dyskinesias are improved by fluoxetine
Durif, F., Vidailhet, M., Bonnet, A. M., Blin, J., & Agid, Y. (1995) · Neurology · doi:10.1212/wnl.45.10.1855 · Cited by 112
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease
Shimoji, M., Zhang, L., Mandir, A. S., Dawson, V. L., & Dawson, T. M. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.01.012 · Cited by 111
Tel, B. C., Zeng, B. ‐., Cannizzaro, C., Pearce, R. K. B., Rose, S., & Jenner, P. G. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00535-3 · Cited by 111
Self-citationFunctional models of Parkinson's disease: A valuable tool in the development of novel therapies
Jenner, P. G. (2009) · Annals of Neurology · doi:10.1002/ana.21489 · Cited by 109
Self-citationYoshimura, N., Mizuta, E., Yoshida, O., & Kuno, S. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37579-2 · Cited by 109
Li, S. J., Jiang, H., Stachowiak, M. S., Hudson, P. M., Owyang, V., Nanry, K. P., Tilson, H. A., & Hong, J. (1990) · Molecular Brain Research · doi:10.1016/0169-328x(90)90020-e · Cited by 108
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism
Halliday, G. M., Herrero, M. T., Murphy, K., McCann, H., Ros‐Bernal, F., Barcia, C., Mori, H., Blesa, F. J., & Obeso, J. A. (2009) · Movement Disorders · doi:10.1002/mds.22481 · Cited by 108
Amalric, M., Moukhles, H., Nieoullon, A., & Daszuta, A. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb01085.x · Cited by 106
Fox, S. H., Lang, A. E., & Brotchie, J. M. (2006) · Movement Disorders · doi:10.1002/mds.20936 · Cited by 105
Hassouna, I. A., Wickert, H., Zimmermann, M., & Gillardon, F. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12323-5 · Cited by 104
Novikova, L., Garris, B. L., Garris, D. R., & Lau, Y.-S. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.007 · Cited by 102
Morissette, M., Grondin, R., Goulet, M., Bédard, P. J., & Paolo, T. D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720682.x · Cited by 101
Luthman, J., Fredriksson, A., Lewander, T., Jonsson, G., & Archer, T. (1989) · Psychopharmacology · doi:10.1007/bf00589907 · Cited by 100
Visanji, N. P., Gómez-Ramírez, J., Johnston, T. H., Pires, D., Voon, V., Brotchie, J. M., & Fox, S. H. (2006) · Movement Disorders · doi:10.1002/mds.21073 · Cited by 100
Grégoire, L., Samadi, P., Graham, J., Bédard, P. J., Bartoszyk, G. D., & Paolo, T. D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.11.001 · Cited by 98
Meissner, W. G., Prunier, C., Guilloteau, D., Chalon, S., Gross, C. E., & Bézard, E. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:3:209 · Cited by 96
Joyce, J. N., Marshall, J. F., Bankiewicz, K. S., Kopin, I. J., & Jacobowitz, D. M. (1986) · Brain Research · doi:10.1016/0006-8993(86)91345-4 · Cited by 96
Herrero, M. T., Lévy, R., Ruberg, M., Luquín, M. R., Villares, J., López-Guillén, J. L., Faucheux, B. A., Javoy-Agid, F., Guridi, J., Agid, Y., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.219 · Cited by 92
Saravanan, K. S., Madathil, S. K., Karuppagounder, S. S., & Mohanakumar, K. P. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.016 · Cited by 92
MPTP‐Induced Hypoactivity in Mice: Reversal by L‐Dopa
Fredriksson, A., Płaźnik, A., Sundström, E., JONSSON, G., & Archer, T. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00833.x · Cited by 92
Pharmacology of dopamine agonists in the treatment of Parkinson’s disease
Jenner, P. G. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s1 · Cited by 91
Self-citationProteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons
Schapira, A. H. V., Cleeter, M. W. J., Muddle, J. R., Workman, J. M., Cooper, J. A. D., & King, R. H. M. (2006) · Annals of Neurology · doi:10.1002/ana.20934 · Cited by 91
Gupta, S. P., Patel, S., Yadav, S., Singh, A. K., Singh, S. K., & Singh, M. P. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0176-5 · Cited by 90
Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Langston, J. W., Quik, M., Petzinger, G. M., Jakowec, M. W., & Monte, D. A. D. (2000) · PubMed · Cited by 89
McNaught, K. S. P., & Jenner, P. G. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00415-9 · Cited by 89
Self-citationPesah, Y., Burgess, H., Middlebrooks, B. W., Ronningen, K., Prosser, J., Tirunagaru, V. G., Zysk, J. R., & Mardon, G. (2005) · genesis · doi:10.1002/gene.20106 · Cited by 88
Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat
Nash, J. E., Hill, M. P., & Brotchie, J. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6963 · Cited by 88
Barnéoud, P., Parmentier, S., Mazadier, M., Miquet, J.-M., Boireau, A., Dubédat, P., & Blanchard, J. C. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00112-v · Cited by 87
Modelling Parkinson‐like neurodegeneration via osmotic minipump delivery of MPTP and probenecid
Alvarez‐Fischer, D., Guerreiro, S., Hunot, S., Saurini, F., Marien, M. R., Sokoloff, P., Hirsch, É. C., Hartmann, A., & Michel, P. P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05651.x · Cited by 87
Paraquat: The Red Herring of Parkinson's Disease Research
Miller, G. W. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm223 · Cited by 87
The behavioural effects of pramipexole, a novel dopamine receptor agonist
Maj, J., Rogóż, Z., Skuza, G., et al. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00066-6 · Cited by 87
Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli, U., Dotto, P. D., & Rascol, O. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70835-1 · Cited by 87
Colebrooke, R. E., Humby, T., Lynch, P. J., McGowan, D., Xia, J., & Emson, P. C. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05143.x · Cited by 86
Li, X., Matsumoto, K., Murakami, Y., et al. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.09.004 · Cited by 86
Sonsalla, P. K., & Heikkila, R. E. (1988) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(88)90054-1 · Cited by 86
Smith, L. A., Jackson, M. J., Hansard, M. J., Maratos, E. C., & Jenner, P. G. (2003) · Movement Disorders · doi:10.1002/mds.10394 · Cited by 86
Self-citationDawson, L., Chadha, A., Megalou, M., & Duty, S. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703105 · Cited by 85
Self-citationBlanchard, V., Chritin, M., Vyas, S., Savasta, M., Feuerstein, C., Agid, Y., Javoy-Agid, F., & Raisman‐Vozari, R. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041669.x · Cited by 85
Barnéoud, P., Descombris, E., Aubin, N., & Abrous, D. N. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00896.x · Cited by 85
C. elegans: a novel pharmacogenetic model to study Parkinson's disease
Nass, R., Miller, D. M., & Blakely, R. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00056-0 · Cited by 85
Barlow, B. K., Thiruchelvam, M. J., Bennice, L., Cory‐Slechta, D. A., Ballatori, N., & Richfield, E. K. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01773.x · Cited by 83
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs
Ezrin‐Waters, C., Muller, P., & Seeman, P. M. (1976) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y76-071 · Cited by 83
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat
Sakai, K., & Gash, D. M. (1994) · Brain Research · doi:10.1016/0006-8993(94)91533-4 · Cited by 82
Visanji, N. P., Orsi, A., Johnston, T. H., Howson, P. A., Dixon, K., Callizot, N., Brotchie, J. M., & Rees, D. D. (2008) · The FASEB Journal · doi:10.1096/fj.07-095398 · Cited by 80
Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease
Fox, S. H., Visanji, N. P., Reyes, G., Huot, P., Gómez-Ramírez, J., Johnston, T. H., & Brotchie, J. M. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009707 · Cited by 78
Paillé, V., Henry, V., Lescaudron, L., Brachet, P., & Damier, P. (2007) · Movement Disorders · doi:10.1002/mds.21308 · Cited by 77
Molecular basis of Parkinson's disease
Yang, Y. X., Wood, N. W., & Latchman, D. S. (2009) · Neuroreport · doi:10.1097/wnr.0b013e32831c50df · Cited by 76
Quik, M., Police, S. M. C., He, L., Monte, D. A. D., & Langston, J. W. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00130-5 · Cited by 75
Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Albanese, A., Jenner, P. G., MARSDEN, C. D., & Stephenson, J. D. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90143-7 · Cited by 75
Self-citationGhosh, B., Antonio, T., Reith, M. E. A., & Dutta, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901618d · Cited by 75
Pifl, C., Schingnitz, G., & Hornykiewicz, O. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90066-3 · Cited by 74
Breit, S., Lessmann, L., Unterbrink, D., Popa, R. C., Gasser, T., & Schulz, J. B. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05106.x · Cited by 74
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders
Speiser, Z., Levy, R., & Cohen, S. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6499-0_29 · Cited by 74
Finberg, J. P. M., & Youdim, M. B. H. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00216-2 · Cited by 72
Löschmann, P., Smith, L. A., Lange, K. W., Jaehnig, P., Jenner, P. G., & MARSDEN, C. D. (1991) · Psychopharmacology · doi:10.1007/bf02244422 · Cited by 71
Self-citationBézard, E., Gerlach, I., Moratalla, R., Gross, C. E., & Jork, R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.003 · Cited by 70
Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain.
Riachi, N. J., LaManna, J. C., & Harik, S. I. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23492-9 · Cited by 70
PITX3 polymorphism is associated with early onset Parkinson's disease
Bergman, O., Håkansson, A. S., Westberg, L., Nordenström, K., Belin, A. C., Sydow, O., Olson, L., Holmberg, B., Eriksson, E., & Nissbrandt, H. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.008 · Cited by 69
Hébert, G. A., Arsaut, J., Dantzer, R., & Demotes‐Mainard, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00832-2 · Cited by 69
Ferraro, T. N., Golden, G. T., DeMattei, M., Hare, T. A., & Fariello, R. G. (1986) · Neuropharmacology · doi:10.1016/0028-3908(86)90205-4 · Cited by 66
M�ller, T., Hefter, H., Hueber, R., Jost, W., Leenders, K., Odin, P., & Schwarz, J. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1610-x · Cited by 66
Vila, M., Herrero, M. T., Lévy, R., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.802 · Cited by 66
Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., & Jenner, P. G. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039743 · Cited by 66
Self-citationFrom the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
Jenner, P. G. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70829-6 · Cited by 65
Self-citationMaj, J., Rogóż, Z., Skuza, G., Sowińska, H., & Superata, J. (1990) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260898 · Cited by 65
Mogi, M., Togari, A., Tanaka, K.-I., Ogawa, N., Ichinose, H., & Nagatsu, T. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01275-1 · Cited by 62
Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats
Saint‐Pierre, M., Tremblay, M., Attila Gabor, S. I. K., Gross, R. E., & Cicchetti, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03923.x · Cited by 62
Effects of MPTP on locomotor activity in mice
Colotla, V. A., Flores, E., Oscos, A., Meneses, A., & Tapia, R. (1990) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(90)90061-g · Cited by 62
GDNF reverses priming for dyskinesia in MPTP‐treated, l ‐DOPA‐primed common marmosets
Iravani, M. M., Costa, S., Jackson, M. J., Tel, B. C., Cannizzaro, C., Pearce, R. K. B., & Jenner, P. G. (2001) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2001.01408.x · Cited by 59
Self-citationGreco, B., Lopez, S., van der Putten, H., Flor, P. J., & Amalric, M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162115 · Cited by 59
Neurochemical bases of tremor and other disorders of movement.
Sourkes, T. L., & POIRIER, L. J. (1966) · PubMed · Cited by 58
van den Munckhof, P., Gilbert, F., Chamberland, M., Lévesque, D., & Drouin, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03522.x · Cited by 58
MacInnes, N., Messenger, M. J., & Duty, S. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705566 · Cited by 58
Self-citationRose, S., Nomoto, M., Kelly, E., Kilpatrick, G. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90550-8 · Cited by 58
Self-citationCadet, J. L., & Zhu, S. M. (1992) · Brain Research · doi:10.1016/0006-8993(92)91066-n · Cited by 57
Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
Jenner, P. G. (1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.suppl.22 · Cited by 56
Self-citationCosta, S., Iravani, M. M., Pearce, R. K. B., & Jenner, P. G. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00933-x · Cited by 56
Self-citationSmith, L. A., Jackson, M. J., Johnston, L. C., Kuoppamäki, M., Rose, S., Al‐Barghouthy, G., Signore, S. D., & Jenner, P. G. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000220818.71231.df · Cited by 55
Self-citationActivity and acceptability of piribedil in Parkinson's disease: a multicentre study
Rondot, P., & Ziegler, M. (1992) · Journal of Neurology · doi:10.1007/bf00819564 · Cited by 54
You, Z. ‐., Herrera‐Marschitz, M., Pettersson, E., Nylander, I., Goiny, M., Shou, H.-Z., Kehr, J., Godukhin, O. V., Hökfelt, T., Terenius, L. Y., et al. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00149-2 · Cited by 53
Inden, M., Kitamura, Y., Tamaki, A., Yanagida, T., Shibaike, T., Yamamoto, A., Takata, K., Yasui, H., Taira, T., Ariga, H., et al. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.07.009 · Cited by 52
Hauser, R. A., Salin, L., Juhel, N., & Konyago, V. L. (2006) · Movement Disorders · doi:10.1002/mds.21258 · Cited by 52
Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease.
Hirsch, É. C., Hunot, S., Damier, P., Brugg, B., Faucheux, B. A., Michel, P. P., Ruberg, M., Muriel, M., Prigent, A., & Agid, Y. (1999) · PubMed · Cited by 52
Long-term studies of dopamine agonists
Hubble, J. P. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s42 · Cited by 51
Pérez‐Otaño, I., Oset, C., Luquín, M. R., Herrero, M. T., Obeso, J. A., & Río, J. D. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91094-4 · Cited by 50
Temlett, J. A., Chong, P. N., Oertel, W. H., Jenner, P. G., & MARSDEN, C. D. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90322-6 · Cited by 50
Self-citationAustin, P. J., Betts, M. J., Broadstock, M., O'Neill, M., Mitchell, S. N., & Duty, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00820.x · Cited by 49
Self-citationBevan, P. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90548-7 · Cited by 49
Visanji, N. P., O’Neill, M. J., & Duty, S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.015 · Cited by 49
Self-citationHerrero, M. T., Augood, S. J., Asensi, H., Hirsch, É. C., Agid, Y., Obeso, J. A., & Emson, P. C. (1996) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00157-x · Cited by 48
Millan, M. J., Cara, B. D., Hill, M. P., Jackson, M., Joyce, J. N., Brotchie, J. M., McGuire, S., Crossman, A. R., Smith, L. A., Jenner, P. G., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062414 · Cited by 48
Self-citationMorissette, M., Goulet, M., Calon, F., Falardeau, P., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09534-3 · Cited by 48
Löschmann, P., Smith, L. A., Lange, K. W., Jähnig, P., Jenner, P. G., & MARSDEN, C. D. (1992) · Psychopharmacology · doi:10.1007/bf02245479 · Cited by 48
Self-citationStriatal neuropeptide levels in Parkinson's disease patients
Fernandez, A., CEBALLOS, M. L. D., Jenner, P., et al. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90014-x · Cited by 47
Self-citationDysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release
McNaught, K. S. P., & Jenner, P. G. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00982-4 · Cited by 46
Self-citationEffects of Ropinirole on Various Parkinsonian Models in Mice, Rats, and Cynomolgus Monkeys
Fukuzaki, K., Kamenosono, T., & Nagata, R. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00240-3 · Cited by 46
Jackson, M. J., Smith, L. A., Al‐Barghouthy, G., Rose, S., & Jenner, P. G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.10.005 · Cited by 46
Self-citationSilverdale, M., Nicholson, S. L., Ravenscroft, P., Crossman, A. R., Millan, M. J., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.03.022 · Cited by 46
Hurley, M. J., Jolkkonen, J., Stubbs, C. M., et al. (1996) · Brain Research · doi:10.1016/0006-8993(95)01309-1 · Cited by 44
Duty, S., & Brotchie, J. M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6431 · Cited by 44
Self-citationInteraction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model
Decamp, E., & Schneider, J. S. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.028 · Cited by 44
Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats
Skuza, G., Rogóż, Z., Quack, G., & Danysz, W. (1994) · Journal of Neural Transmission · doi:10.1007/bf01277594 · Cited by 43
Grealish, S., Xie, L., Kelly, M., & Dowd, E. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.08.018 · Cited by 42
Haque, Z., Lee, T. K. M., Inoue, T., Luk, C., Hasan, S. U., Lukowiak, K., & Syed, N. I. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04543.x · Cited by 41
Pearce, R. K. B., Smith, L. A., Jackson, M. J., Banerji, T., Scheel‐Krüger, J., & Jenner, P. G. (2002) · Movement Disorders · doi:10.1002/mds.10238 · Cited by 41
Self-citationEntacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets
Smith, L. A., Gordin, A., Jenner, P. G., & MARSDEN, C. D. (1997) · Movement Disorders · doi:10.1002/mds.870120616 · Cited by 40
Self-citationVisanji, N. P., Fox, S. H., Johnston, T. H., Millan, M. J., & Brotchie, J. M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144097 · Cited by 40
Törnwall, M., & Männistö, P. T. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90623-p · Cited by 39
Liou, H., Chen, R.-C., Chen, T. H.-H., Tsai, Y., & Tsai, M.-C. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9130 · Cited by 38
Gibb, W. R. G., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90123-0 · Cited by 38
Self-citationNurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo
Pan, T., Zhu, W., Zhao, H., Deng, H., Xie, W., Jankovic, J. J., & Le, W. (2008) · Brain Research · doi:10.1016/j.brainres.2008.05.022 · Cited by 36
Kunikowska, G., & Jenner, P. G. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03149-3 · Cited by 35
Self-citationL-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates
Kuoppamäki, M., Al‐Barghouthy, G., Jackson, M. J., Smith, L. A., Quinn, N. P., & Jenner, P. G. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0727-3 · Cited by 34
Self-citationCalon, F., Lavertu, N., Lemieux, A., et al. (2001) · Synapse · doi:10.1002/syn.1045 · Cited by 34
Effects of Dopamine Denervation on Striatal Peptide Expression in Parkinsonian Monkeys
Lavoie, B. A., Parent, A., & Bédard, P. J. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100032467 · Cited by 34
Schmidt, W., Lebsanft, H. B., Heindl, M., Gerlach, M., Grünblatt, E., Riederer, P. F., Mayerhofer, A., & Scheller, D. K. A. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0102-z · Cited by 33
Jones, C. A., Johnston, L. C., Jackson, M. J., Smith, L. A., Scharrenburg, G. J. M. V., Rose, S., Jenner, P. G., & McCreary, A. C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.001 · Cited by 33
Self-citationStockwell, K., Virley, D. J., Perren, M. J., Iravani, M. M., Jackson, M. J., Rose, S., & Jenner, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.01.019 · Cited by 33
Self-citationNeuroleptic-induced catalepsy as a model of Parkinson's disease I. Effect of dopaminergic agents
Elliott, P. J., Close, S. P., Walsh, D. M., Hayes, A. G., & Marriott, A. S. (1990) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260896 · Cited by 32
Viaro, R., Marti, M., & Morari, M. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.01.014 · Cited by 32
The Protective Effects of PBN Against MPTP Toxicity Are Independent of Hydroxyl Radical Trapping
Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K., & Oertel, W. H. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00229-4 · Cited by 28
Tayarani‐Binazir, K. A., Jackson, M. J., Rose, S., McCreary, A. C., & Jenner, P. G. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.09.007 · Cited by 28
Self-citationDopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates
Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., & Jenner, P. G. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02268-9 · Cited by 28
Self-citationGibb, W. R. G., Terruli, M., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Movement Disorders · doi:10.1002/mds.870040109 · Cited by 27
Self-citationSynergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice
Fredriksson, A., & Archer, T. (1995) · Journal of Neural Transmission · doi:10.1007/bf01276562 · Cited by 27
Johnels, B. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90082-x · Cited by 26
Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist
Heinrich, J. N., Brennan, J. A., LAI, M. H., Sullivan, K., Hornby, G., Popiolek, M., Jiang, L.-X., Pausch, M. H., Stack, G., Marquis, K. L., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.08.063 · Cited by 26
Blanchet, P. J., Konitsiotis, S., Hyland, Κ., Arnold, L. A., Pettigrew, K. D., & Chase, T. N. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6906 · Cited by 25
Vernon, A. C., Croucher, M. J., & Dexter, D. T. (2008) · Neuroreport · doi:10.1097/wnr.0b013e3282f602df · Cited by 23
Um, J. W., Park, H. J., Song, J., Jeon, I., Lee, G., Lee, P. H., & Chung, K. C. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.090 · Cited by 23
DESHAIES, P., BEDARD, P., Falardeau, P., & Paolo, T. D. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90243-0 · Cited by 20
Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., & Jenner, P. G. (2004) · Movement Disorders · doi:10.1002/mds.10596 · Cited by 18
Self-citationMarı́n, C., Aguilar, E., Mengod, G., Cortés, R., & Obeso, J. A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05265.x · Cited by 17
Johnston, L. C., Jackson, M. J., Rose, S., McCreary, A. C., & Jenner, P. G. (2010) · Movement Disorders · doi:10.1002/mds.23249 · Cited by 17
Self-citationJackson, M., Andree, T., Hansard, M. J., Hoffman, D., Hurtt, M., Kehne, J., Pitler, T. A., Smith, L. A., Stack, G., & Jenner, P. (2009) · Journal of neural transmission · doi:10.1007/s00702-009-0323-9 · Cited by 15
Self-citationFrom Drugs of Abuse to Parkinsonism: The MPTP Mouse Model of Parkinson's Disease
Lau, Y., & Meredith, G. E. (2003) · Humana Press eBooks · doi:10.1385/1-59259-358-5:103 · Cited by 15
Johnston, T. H., & Duty, S. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705372 · Cited by 10
Self-citationBukhatwa, S., Zeng, B., Rose, S., & Jenner, P. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.060 · Cited by 7
Self-citationLangston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
Parkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
Self-citationHuman symptoms–disease network
Zhou, X., Menche, J., Barabási, A.-L., & Sharma, A. (2014) · Nature Communications · doi:10.1038/ncomms5212 · Cited by 653
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Johnson, M. E., & Bobrovskaya, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 332
Parkinson’s Disease: Pathogenesis and Clinical Aspects
(2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018 · Cited by 294
Metadata
- Authors
- Duty, S., & Jenner, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-10
- Volume
- 164
- Issue
- 4
- Pages
- 1357-1391
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1502339857
- Cited by
- 753
- References
- 399
- FWCI
- 21.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.